Imaging of atherosclerosis

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 25-40

  Owen, D R J ^a,b   Lindsay, A C ^c   Choudhury, R P ^c   Fayad, Z A ^d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Translational and Molecular Imaging Institute   (United States)

Author keywords

CT; MRI; PET; ultrasound; vulnerable plaque

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; IMAGING; INTRAVASCULAR ULTRASOUND; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOGENESIS;

ANIMALS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CAROTID STENOSIS; CONSTRICTION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79551574750     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-041709-133809     Document Type: Article

References (102)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. 2010. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121(7):e46-e215
2. Hellings WE, Peeters W, Moll FL, et al. 2007. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc. Med. 17(5):162-71
3. Hackett D, Davies G, Maseri A 1988. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur. Heart J 9(12) 1317-23
4. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-89
5. Topol EJ, Nissen SE. 1995. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92(8):2333-42
6. Corti R, Fuster V, Fayad ZA, et al. 2002. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-upbyhigh-resolution noninvasive magnetic resonance imaging. Circulation 106(23):2884-87
7. Corti R, Fayad ZA, Fuster V, et al. 2001. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104(3):249-52
8. Lee JM, Robson MD, Yu LM, et al. 2009. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol. 54(19):1787-94
9. Schaar JA, Muller JE, Falk E, et al. 2004. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur. Heart J. 25(12):1077-82
10. Thoenes M, Oguchi A, Nagamia S, et al. 2007. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markersinpatients with the metabolic syndrome. Int. J. Clin. Pract. 61(11):1942-48
11. de GE, Jukema JW, van Boven AJ, et al. 1995. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am. J. Cardiol. 76(9):40C-46C
12. Crouse JR III, Byington RP, Bond MG, et al. 1995. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am. J. Cardiol. 75(7):455-59
13. Crouse JR III, Raichlen JS, Riley WA, et al. 2007. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297(12):1344-53
14. Simons PC, Algra A, Bots ML, et al. 1999. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 100(9):951-57
15. Hodis HN, Mack WJ, LaBree L, et al. 1998. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128(4):262-69
16. Yamasaki Y, Kodama M, Nishizawa H, et al. 2000. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23(9):1310-15
17. Bots ML, Hoes AW, Koudstaal PJ, et al. 1997. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96(5):1432-37
18. Bots ML, Evans GW, Riley WA, et al. 2003. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 34(12):2985-94
19. Finn AV, Kolodgie FD, Virmani R. 2010. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler. Thromb. Vasc. Biol. 30(2):177-81
20. Beere PA, Glagov S, Zarins CK. 1992. Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Localization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler. Thromb. 12(11):1245-53
21. Young W, Gofman JW, Tandy R, et al. 1960. The quantitation of atherosclerosis. II. Quantitative aspects of the relationship of blood pressure and atherosclerosis. Am. J. Cardiol. 6:294-99
22. O'Leary DH, Polak JF, Kronmal RA, et al. 1999. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340(1):14-22
23. Crouse JR III, Craven TE, Hagaman AP, et al. 1995. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 92(5):1141-47
24. Howard G, Sharrett AR, Heiss G, et al. 1993. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24(9):1297-304
25. Malek AM, Alper SL, Izumo S. 1999. Hemodynamic shear stress and its role in atherosclerosis. JAMA 282(21):2035-42
26. Owen DR, Shalhoub J, Miller S, et al. 2010. Inflammation within carotid atherosclerotic plaque: assessment with late-phase contrast-enhanced US. Radiology 255(2):638-44
27. Shah F, Balan P, Weinberg M, et al. 2007. Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: a new surrogate marker of atherosclerosis? Vasc. Med. 12(4):291-97
28. Coli S, Magnoni M, Sangiorgi G, et al. 2008. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity. J. Am. Coll. Cardiol. 52(3):223-30
29. Staub D, Patel MB, Tibrewala A, et al. 2010. Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events. Stroke 41(1):41-47
30. Xiong L, Deng YB, Zhu Y, et al. 2009. Correlation of carotid plaque neovascularization detected by using contrast-enhanced US with clinical symptoms. Radiology 251(2):583-89
31. Tsutsui JM, Xie F, Cano M, et al. 2004. Detection of retained microbubbles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction. J. Am. Coll. Cardiol. 44(5):1036-46
32. Lindner JR, Coggins MP, Kaul S, et al. 2000. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin- and complement-mediated adherence to activated leukocytes. Circulation 101(6):668-75
33. Kaufmann BA, Sanders JM, Davis C, et al. 2007. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116(3):276-84
34. Leong-Poi H, Christiansen J, Heppner P, et al. 2005. Assessment of endogenous and therapeutic arteri-ogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 111(24):3248-54
35. Glagov S, Weisenberg E, Zarins CK, et al. 1987. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316(22):1371-75
36. Tobis JM, Mallery J, Mahon D, et al. 1991. Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens. Circulation 83(3):913-26
37. Yamagishi M, Terashima M, Awano K, et al. 2000. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J. Am. Coll. Cardiol. 35(1):106-11
38. Prati F, Arbustini E, Labellarte A, et al. 2001. Correlation between high frequency intravascular ultrasound and histomorphology in human coronary arteries. Heart 85(5):567-70
39. Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9):1071-80
40. Nissen SE, Nicholls SJ, Sipahi I, et al. 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556-65
41. Nissen SE, Tsunoda T, Tuzcu EM, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17):2292-300
42. Nissen SE, Tardif JC, Nicholls SJ, et al. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356(13):1304-16
43. Vergeer M, Bots ML, van Leuven SI, et al. 2008. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118(24):2515-22
44. Mintz GS, Nissen SE, Anderson WD, et al. 2001. American College of Cardiology clinical expert consensus document onstandards for acquisition, measurement and reportingofintravascular ultrasound studies (IVUS).Areportof the American CollegeofCardiology Task Force onClinical Expert Consensus Documents. J. Am. Coll. Cardiol. 37(5):1478-92
45. Nasu K, Tsuchikane E, Katoh O, et al. 2006. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J. Am. Coll. Cardiol. 47(12):2405-12
46. Serruys PW, Garcia-Garcia HM, Buszman P, et al. 2008. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11):1172-82
47. Sanz J, Fayad ZA. 2008. Imaging of atherosclerotic cardiovascular disease. Nature 451(7181):953-57
48. Yuan C, Mitsumori LM, Beach KW, et al. 2001. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 221(2):285-99
49. Cai JM, Hatsukami TS, Ferguson MS, et al. 2002. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 106(11):1368-73
50. Fayad ZA, Nahar T, Fallon JT, et al. 2000. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101(21):2503-9
51. Chan SK, Jaffer FA, Botnar RM, et al. 2001. Scan reproducibility of magnetic resonance imaging assessment of aortic atherosclerosis burden. J. Cardiovasc. Magn. Reson. 3(4):331-38
52. Yuan C, Zhang SX, Polissar NL, et al. 2002. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105(2):181-85
53. Lee JM, Wiesmann F, Shirodaria C, et al. 2008. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 197(2):951-58
54. Yuan C, Kerwin WS, Ferguson MS, et al. 2002. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J. Magn. Reson. Imaging 15(1):62-67
55. Kerwin W, Hooker A, Spilker M, et al. 2003. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 107(6):851-56
56. Kerwin WS, O'Brien KD, Ferguson MS, et al. 2006. Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241(2):459-68
57. Briley-Saebo KC, Mulder WJ, ManiV,etal. 2007. Magnetic resonance imagingofvulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J. Magn. Reson. Imaging 26(3):460-79
58. Tang TY, Howarth SP, Miller SR, et al. 2009. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 53(22):2039-50
59. McAteer MA, Schneider JE, Ali ZA, et al. 2008. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 28(1):77-83
60. Frias JC, Williams KJ, Fisher EA, et al. 2004. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126(50):16316-17
61. Detrano R, Guerci AD, Carr JJ, et al. 2008. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N. Engl. J. Med. 358(13):1336-45
62. Sangiorgi G, Rumberger JA, Severson A, et al. 1998. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J. Am. Coll. Cardiol. 31(1):126-33
63. Schuijf JD, van der Wall EE, Bax JJ. 2009. Lesions without calcium: lessons from CT angiography. Heart 95(13):1038-40
64. Ferencik M, Chan RC, Achenbach S, et al. 2006. Arterial wall imaging: evaluation with 16-section multidetector CT in blood vessel phantoms and ex vivo coronary arteries. Radiology 240(3):708-16
65. McCullough PA, Chinnaiyan KM. 2009. Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch. Intern. Med. 169(22):2064-70
66. Hyafil F, Cornily JC, Feig JE, et al. 2007. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13(5):636-41
67. Cormode DP, Frias JC, Ma Y, et al. 2009. HDL as a contrast agent for medical imaging. Clin. Lipidol. 4(4):493-500
68. Einstein AJ, Henzlova MJ, Rajagopalan S. 2007. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 298(3):317-23
69. Einstein AJ, Elliston CD, Arai AE, et al. 2010. Radiation dose from single-heartbeat coronary CT angiography performed with a 320-detector row volume scanner. Radiology 254(3):698-706
70. Lehman SJ, Schlett CL, Bamberg F, et al. 2009. Assessment of coronary plaque progression in coronary computed tomography angiography using a semiquantitative score. JACC Cardiovasc. Imaging 2(11):1262-70
71. Meijboom WB, Mollet NR, Van Mieghem CA,etal. 2007. 64-Slice CT coronary angiography inpatients with non-ST elevation acute coronary syndrome. Heart 93(11):1386-92
72. Ohtsuki K, Hayase M, Akashi K, et al. 2001. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 104(2): 203-8
73. Haubner R. 2006. αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging 33(Suppl. 1):54-63
74. Virgolini I, Rauscha F, Lupattelli G, et al. 1991. Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage. Eur. J. Nucl. Med. 18(12):948-51
75. Choudhary S, Higgins CL, Chen IY, et al. 2006. Quantitation and localization of matrix metallopro-teinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler. Thromb. Vasc. Biol. 26(10):2351-58
76. Greco C, Di LM, Ciavolella M, et al. 1993. Immunodetection of human atherosclerotic plaque with 125I-labeled monoclonal antifibrin antibodies. Atherosclerosis 100(2):133-39
77. Langer HF, Haubner R, Pichler BJ, et al. 2008. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J. Am. Coll. Cardiol. 52(1):1-12
78. Rudd JH, Warburton EA, Fryer TD, et al. 2002. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105(23):2708-11
79. Tawakol A, Migrino RQ, Bashian GG, et al. 2006. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48(9):1818-24
80. Pedersen SF, Graebe M, Fisker Hag AM, et al. 2010. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl. Med. Commun. 31(5):423-29
81. Tahara N, Kai H, Ishibashi M, et al. 2006. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48(9):1825-31
82. Lee SJ, On YK, Lee EJ, et al. 2008. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J. Nucl. Med. 49:1277-82
83. Rudd JH, Myers KS, Bansilal S, et al. 2008. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J. Nucl. Med. 49(6):871-78
84. Wykrzykowska J, Lehman S, Williams G, et al. 2009. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J. Nucl. Med. 50(4):563-68
85. Rogers IS, Nasir K, Figueroa AL, et al. 2010. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc. Imaging 3(4):388-97
86. Rominger A, Saam T, Wolpers S, et al. 2009. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J. Nucl. Med. 50(10):1611-20
87. Papadopoulos V, Baraldi M, Guilarte TR, et al. 2006. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27(8):402-9
88. Banati RB, Newcombe J, Gunn RN, et al. 2000. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt. 11):2321-37
89. Imaizumi M, Briard E, Zoghbi SS, et al. 2008. Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 39(3):1289-98
90. Fujimura Y, Hwang PM, Trout IH, et al. 2008. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis 201:108-11
91. Pugliese F, Gaemperli O, Kinderlerer AR, et al. 2010. Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J. Am. Coll. Cardiol. 56:653-61
92. Chauveau F, Boutin H, Van Camp N, et al. 2008. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging 35(12):2304-19
93. Owen DR, Howell OW, Tang SP, et al. 2010. Two binding sites for [(3)H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J. Cereb. Blood Flow Metab. 30:1608-18
94. Owen DRJ, Gunn RN, Rabiner EA,etal. 2010. Mixed affinity bindinginhumans with18kDa translocator protein (TSPO) ligands. J. Nucl. Med. In press
95. Boggs KP, Rock CO, Jackowski S. 1995. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J. Biol. Chem. 270(13):7757-64
96. Matter CM, Wyss MT, Meier P, et al. 2006. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler. Thromb. Vasc. Biol. 26(3):584-89
97. Roivainen A, Yli-Kerttula T. 2006. Whole-body distribution of (11)C-choline and uptake in knee syn-ovitis. Eur. J. Nucl. Med. Mol. Imaging 33(11):1372-73
98. Kato K, Schober O, Ikeda M, et al. 2009. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur. J. Nucl. Med. Mol. Imaging 36(10):1622-28
99. Bucerius J, Schmaljohann J, Bohm I, et al. 2008. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results. Eur. J. Nucl. Med. Mol. Imaging 35(4):815-20
100. Ben Haim S, Kupzov E, Tamir A, et al. 2004. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J. Nucl. Med. 45(11):1816-21
101. Skajaa T, Cormode DP, Falk E, et al. 2010. High-density lipoprotein-based contrast agents for multi-modal imaging of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30(2):169-76
102. Cormode DP, Briley-Saebo KC, Mulder WJ, et al. 2008. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4(9):1437-44